We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.3B
AUM Growth
-$16.8M
Cap. Flow
-$266M
Cap. Flow %
-5.01%
Top 10 Hldgs %
22.18%
Holding
297
New
35
Increased
74
Reduced
86
Closed
35

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$60.5M
2
SPGI icon
S&P Global
SPGI
+$52.3M
3
BMY icon
Bristol-Myers Squibb
BMY
+$41.3M
4
AGN
Allergan plc
AGN
+$38.2M
5
LVNTA
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
+$37.2M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$98.3M
2
LLY icon
Eli Lilly
LLY
+$54.1M
3
AAPL icon
Apple
AAPL
+$51.2M
4
FIS icon
Fidelity National Information Services
FIS
+$42.9M
5
SYK icon
Stryker
SYK
+$40.2M

Sector Composition

Rank Sector Weight
1 Healthcare 25.18%
2 Financials 21.66%
3 Technology 21.39%
4 Communication Services 9.45%
5 Consumer Discretionary 5.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QLYS icon
251
Qualys
QLYS
$4.84B
– –
-61,002
Closed -$1.54M
SAGE
252
DELISTED
Sage Therapeutics
SAGE
– –
-160,000
Closed -$5.13M
SYK icon
253
Stryker
SYK
$127B
– –
-375,002
Closed -$40.2M
SYNA icon
254
Synaptics
SYNA
$4.41B
– –
-137,627
Closed -$11M
TTWO icon
255
Take-Two Interactive
TTWO
$43B
– –
-30,000
Closed -$1.12M
TWO
256
Two Harbors Investment
TWO
$1.27B
– –
-25,000
Closed -$1.59M
SRCL
257
DELISTED
Stericycle Inc
SRCL
– –
-157,400
Closed -$19.9M
ACOR
258
DELISTED
Acorda Therapeutics
ACOR
– –
-242
Closed -$768K
CERN
259
DELISTED
Cerner Corp
CERN
– –
-41,742
Closed -$2.21M
MIME
260
DELISTED
Mimecast Limited
MIME
– –
-116,432
Closed -$1.13M
NBRV
261
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-120
Closed -$269K
DATA
262
DELISTED
Tableau Software, Inc.
DATA
– –
-105,360
Closed -$4.83M
AET
263
DELISTED
Aetna Inc
AET
– –
-226,556
Closed -$25.5M
CALD
264
DELISTED
Callidus Software, Inc.
CALD
– –
-309,149
Closed -$5.15M
CEMP
265
DELISTED
Cempra, Inc.
CEMP
– –
-20,000
Closed -$350K
BHI
266
DELISTED
Baker Hughes
BHI
– –
-279,997
Closed -$12.3M
ZLTQ
267
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-200,000
Closed -$5.43M
HAR
268
DELISTED
Harman International Industries
HAR
– –
-27,196
Closed -$2.42M
AMSG
269
DELISTED
Amsurg Corp
AMSG
– –
-96,934
Closed -$7.23M
CVT
270
DELISTED
CVENT, INC.
CVT
– –
-230,905
Closed -$4.94M
TBRA
271
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-50,000
Closed -$409K
CAVM
272
DELISTED
Cavium, Inc.
CAVM
– –
-198,102
Closed -$12.1M
VRML
273
DELISTED
Vermillion, Inc.
VRML
– –
-100,000
Closed -$147K
LNKD
274
DELISTED
LinkedIn Corporation
LNKD
– –
-104,662
Closed -$12M
MDVN
275
DELISTED
MEDIVATION, INC.
MDVN
– –
-86,771
Closed -$3.99M
8 9 10
11
12

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Polar Capital held 297 positions worth $5.3B, down 0.32% from $5.32B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Polar Capital withdrew a net $266M in Q2 2016, closing 35 positions and reducing 86 holdings. Its most notable exit was Stryker, an estimated $40.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Financials and Technology.

Against the trend, Polar Capital opened a new position in S&P Global worth $52.2M.

  • Polar Capital's largest Q2 2016 buy was S&P Global: 487,049 shares worth $52.2M.
  • Polar Capital added most to Pfizer in Q2 2016, an estimated $60.5M increase.
  • Polar Capital's biggest Q2 2016 reduction was Johnson & Johnson, cutting an estimated $98.3M.
  • Polar Capital fully exited Stryker in Q2 2016, selling an estimated $40.2M.
  • Polar Capital's ten largest holdings make up 22% of its $5.3B portfolio in Q2 2016.
  • Polar Capital opened 35 new positions and closed 35 in Q2 2016.
  • Polar Capital's portfolio value fell 0.32% quarter-over-quarter to $5.3B.

Based on Polar Capital's 13F filing for Q2 2016, filed 15 Aug 2016.